Shippeo Launches Second Edition of Visibility Now!, the Premier Event for Supply Chain & Transportation Visibility
10.11.2021 11:15:00 EET | Business Wire | Press release
Shippeo, a global leader and European specialist in real-time transportation visibility, has announced the second edition of its customer community event Visibility Now! in partnership with Savoye, TESISQUARE®, and Siemens Digital Logistics. The hybrid event will take place both online and in-person in Paris on November 17 and offer a unique experience for all participants no matter where they are. From keynotes to customer testimonials and workshops and expert sessions, participants will have the chance to discover product insights and benefit from the expert’s points of view.
With covid border restrictions, container and driver shortages as well as the recent Suez Canal obstruction, now is the time for organizations to build resilient supply chains and visibility as a key enabler.
The event will include speakers from leading international organizations who will share their experiences on working with visibility solutions, outlining the critical roles they play in their digital transformation initiatives, and covering topics such as supply chain automation, global supply chain management, customer-centric approach and product innovation. Participants will have the opportunity to:
- Hear industry leaders discuss their experiences and best practices, including speakers from Renault Group, Coca-Cola HBC, DHL Freight, Nexans, Leroy Merlin, Philip Morris International, and Magnus Logistics
- Listen to top experts covering the latest trends, innovations, and guidelines to ensure transportation visibility project success such as Dr. John Gattorna, Siemens Digital Logistics, Savoye and TESISQUARE®
- Enjoy complimentary access to exclusive recorded sessions to dive deeper into trending topics on supply chain management and visibility
- Meet and engage with Shippeo’s team, alongside other Shippeo users and industry peers throughout the day
Global Supply Chain thought leader, Dr. John Gattorna, will share insights on designing future supply chains with embedded resilience, the challenges of operating global supply chain networks, and embracing multi-modal transportation as an integral part of future supply chains. He will also touch on the future role of 3PLs and 4PLs as genuine partners in the extended supply chain.
The event will include a live 90-minute plenary live show, broadcast from Paris in a dynamic and interactive format where participants will discover the latest insights, trends, and innovations related to supply chain and transportation visibility across a number of industry sectors. Several workshops and expert sessions will be held on demand for a deep dive into trending topics and best practices. These interactive workshops will provide an opportunity for participants to interact with other market leaders facing similar challenges and hear more about the latest news, insights, and product innovations in supply chain and transportation visibility from Shippeo experts.
“In the midst of supply chain disruptions, businesses have come to realize the value of real-time visibility and the need to take action, and further engage in digital transformation processes. We’re delighted to showcase the must-attend transportation visibility event and offer participants a place where they can hear from top industry experts, interact with other shippers, carriers, and logistics service providers from across the ecosystem to share and discover new ways to leverage visibility,” says Lucien Besse, COO of Shippeo.
The live show will stream from 1.30 pm on Wednesday 17th November. More information about the agenda, speakers, and how to register for the free event is available at shippeo.com/visibilitynow
About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 850+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Over 100 customers, including global brands like Coca-Cola HBC, Carrefour, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 25 million shipments per year across 74 countries. Learn more at www.shippeo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005610/en/
Contact information
Audrey Emanuel, audrey.emanuel@shippeo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom